BioPharma« Terug naar discussie overzicht

1. [verwijderd] 30 mei 2009 22:18

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   buy some!!!!!hehehehe gr leguaan
2. [verwijderd] 30 mei 2009 22:21

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Saturday, 30 May 2009 04:22
   
   Advanced Life Sciences (OTC:ADLS) has been on our radar screen for a few weeks as one of our Extreme FDA Trades, but it may continue to climb based on its pending New Drug Application for a once-daily antibiotic for the treatment of adults with mild to moderate community acquired pneumonia (CAP). It has a PDUFA decision date of 7/31/09.
   
   The stock rose +42.42 % on Friday after getting good news from Food and Drug Administration scientists on Friday. Studies involving Advanced Life Sciences Holdings Inc.'s pneumonia drug revealed no unexpected safety concerns. Clinical studies involving the drug, Restanza, revealed safety concerns that are common with other types of pneumonia and bacterial antibiotics, including diarrhea, nausea and headaches, FDA scientists said.
   The stock shot up from $.99 and reached a high of $1.60 on Friday as it continues to trade well above it's 50 day moving average. Before the close, the stock price settled at $1.41. Traders expect that the stock price will continue to climb on Monday, but the extreme price action could come on Tuesday as an FDA-sponsored panel of medical experts will discuss Restanza on that day. They could recommend whether to approve the drug, according to a report from the Wall Street Journal.
   
   If approved, Restanza would treat patients over the age of 18 who suffer from community-acquired pneumonia. Roughly 1 million people over the age of 65 suffer from the infection annually, with symptoms that include fever and hypothermia. Infection can often result in death.
   
   The company announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the June 2, 2009 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. At the meeting, the AIDAC will review and discuss Advanced Life Sciences' New Drug Application (NDA) for Restanza(TM) (cethromycin) in the proposed indication of outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP).
   
   Briefing documents from FDA and Advanced Life Sciences can be found on FDA's website at www.fda.gov/ohrms/dockets/ac/09/brief... According to those documents and medical reporters who have studied them, Restanza revealed "a mixed picture of effectiveness when compared to current antibiotics." In other words, while several studies showed Restanza was slightly better than current antibiotics, such as clarithromycin, other studies showed current treatments were more effective than Restanza.
   
   Advanced Life Sciences is planning a conference call for the morning of Wednesday, June 3, to discuss the results of the June 2nd AIDAC Meeting. Additional call information will be forthcoming.
   
   Advanced Life Sciences acquired the antibiotic in 2005 from Abbott Laboratories (ABT). Abbott studied the antibiotic from 1999 to 2002 but stopped developing it. The FDA said Abbott's studies don't provide much evidence for Restanza's effectiveness, but do contribute to the product's safety profile.
   
   Biotech investors interested in subscribing to our complete database of Clinical Trials and upcoming FDA decisions can access that information at the link below:
   
   biomedreports.com/component/content/a...
   
   Disclosure: No Positions
   
   
   
3. [verwijderd] 1 juni 2009 16:02

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   panel morgen!!!!!!!!!!!!!!!!!
4. [verwijderd] 2 juni 2009 15:54

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   leguaan3 schreef:

   panel morgen!!!!!!!!!!!!!!!!!
   

   benieuwd of we een pos panel krijgen..... indien ja 50 tot 300% erbij???????????
5. [verwijderd] 2 juni 2009 19:40

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Hopelijk had je er niet te veel.
6. [verwijderd] 2 juni 2009 20:01

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   0,27 nu pffffff
7. ludwig mack 2 juni 2009 21:07

   auteur info

   •    ludwig mack

     Lid sinds: 30 jan 2004

     Laatste bezoek: 31 mei 2024

   •    Aanbevelingen

     Ontvangen: 412

     Gegeven: 29

   •    Aantal posts: 8.675

   pump artikel dat iedereen toegstuurd krijgt .........; doe je eigen onderzoek!
   gr
   
   

   quote:

   leguaan3 schreef:

   Saturday, 30 May 2009 04:22
   
   Advanced Life Sciences (OTC:ADLS) has been on our radar screen for a few weeks as one of our Extreme FDA Trades, but it may continue to climb based on its pending New Drug Application for a once-daily antibiotic for the treatment of adults with mild to moderate community acquired pneumonia (CAP). It has a PDUFA decision date of 7/31/09.
   
   The stock rose +42.42 % on Friday after getting good news from Food and Drug Administration scientists on Friday. Studies involving Advanced Life Sciences Holdings Inc.'s pneumonia drug revealed no unexpected safety concerns. Clinical studies involving the drug, Restanza, revealed safety concerns that are common with other types of pneumonia and bacterial antibiotics, including diarrhea, nausea and headaches, FDA scientists said.
   The stock shot up from $.99 and reached a high of $1.60 on Friday as it continues to trade well above it's 50 day moving average. Before the close, the stock price settled at $1.41. Traders expect that the stock price will continue to climb on Monday, but the extreme price action could come on Tuesday as an FDA-sponsored panel of medical experts will discuss Restanza on that day. They could recommend whether to approve the drug, according to a report from the Wall Street Journal.
   
   If approved, Restanza would treat patients over the age of 18 who suffer from community-acquired pneumonia. Roughly 1 million people over the age of 65 suffer from the infection annually, with symptoms that include fever and hypothermia. Infection can often result in death.
   
   The company announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the June 2, 2009 Anti-Infective Drugs Advisory Committee (AIDAC) meeting. At the meeting, the AIDAC will review and discuss Advanced Life Sciences' New Drug Application (NDA) for Restanza(TM) (cethromycin) in the proposed indication of outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP).
   
   Briefing documents from FDA and Advanced Life Sciences can be found on FDA's website at www.fda.gov/ohrms/dockets/ac/09/brief... According to those documents and medical reporters who have studied them, Restanza revealed "a mixed picture of effectiveness when compared to current antibiotics." In other words, while several studies showed Restanza was slightly better than current antibiotics, such as clarithromycin, other studies showed current treatments were more effective than Restanza.
   
   Advanced Life Sciences is planning a conference call for the morning of Wednesday, June 3, to discuss the results of the June 2nd AIDAC Meeting. Additional call information will be forthcoming.
   
   Advanced Life Sciences acquired the antibiotic in 2005 from Abbott Laboratories (ABT). Abbott studied the antibiotic from 1999 to 2002 but stopped developing it. The FDA said Abbott's studies don't provide much evidence for Restanza's effectiveness, but do contribute to the product's safety profile.
   
   Biotech investors interested in subscribing to our complete database of Clinical Trials and upcoming FDA decisions can access that information at the link below:
   
   biomedreports.com/component/content/a...
   
   Disclosure: No Positions
   
   
   
   

8. [verwijderd] 5 juni 2009 09:44

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   weet er iemand waarom je geen OTC kan kopen bij BinckBank ?
   iemand ervaring mee?
   
   
9. Hugo P. 5 juni 2009 11:41

   auteur info

   •    Hugo P.

     Lid sinds: 19 jan 2008

     Laatste bezoek: 06 nov 2023

   •    Aanbevelingen

     Ontvangen: 8

     Gegeven: 5

   •    Aantal posts: 40

   Kan wel, maar dan moet je eerst een apart formulier downlaoden,ondertekenen en naar hen opsturen.
10. [verwijderd] 5 juni 2009 11:43

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    wie heet er ervaring met OTC markt?
    heb begrepen dat het meer risico is..
11. [verwijderd] 5 juni 2009 11:52

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Habeb schreef:

    wie heet er ervaring met OTC markt?
    heb begrepen dat het meer risico is..
    

    waarom otcb doen als er plenty nasdaq/nys stock zijn met ook volatief etc
    
    otcb= bijna geen regulering en minder transparante order boekjes